



DR. REDDY'S INSTITUTE OF LIFE SCIENCES
University of Hyderabad Campus
Gachibowli, Hyderabad 500046, India
Tel: + 91 40 66571500

CONTACT

MEDIA RELATIONS

CALVIN PRINTER
calvinprinter@drreddys.com
(Ph: +91-40- 49002121)

Dr. Reddy's Institute of Life Sciences organises DRILS Synergy 2015

Hyderabad, India, August 29, 2015

Dr. Reddy's Institute of Life Sciences (DRILS), the state-of-the-art research center, conducted a day long symposium "**DRILS Synergy 2015**" with the objective of fostering the "industry academia ecosystem". The event was attended by many eminent leaders including **Shri Y S Chowdary, Union Minister of State, Ministry of Science & Technology & Earth Sciences, Dilip Shanghvi, Founder & Managing Director - Sun Pharma Ltd., Satish Reddy, Chairman – Dr. Reddy's Laboratories and GV Prasad, Co-Chairman and CEO – Dr. Reddy's Laboratories**, besides delegates from leading pharmaceutical companies and premier academic and research institutions.

Dr. Reddy's Institute of Life Sciences is an autonomous body, originally incorporated in 2004 as Institute of Life Sciences (ILS). It is a not-for-profit organization set up under public-private partnership (PPP) model, between the Govt. of Andhra Pradesh & University of Hyderabad and Dr. Reddy's Laboratories Ltd. In Sep 2012, the Institute was renamed as Dr. Reddy's Institute of Life Sciences in honor of the Late Dr. Kallam Anji Reddy, Founder Chairman, Dr. Reddy's, for his pioneering contributions in the area of pharmaceuticals, his passion for research and his generous support which, was instrumental in making this institute a reality.

DRILS Synergy 2015 is a first-of-its-kind program that brought together industry leaders and academia under one roof to discuss opportunities to build a culture of innovation and translational research in India. As part of the program, two panel discussions* were held broadly covering the larger topics of :– **(1) Synergistic Industry Academic Ecosystem: "Innovate in India"** and **(2) "De-risking innovation and gearing up for the future: A perspective in the life sciences"**

Speaking at the occasion, GV Prasad, Co-Chairman & CEO – Dr. Reddy's Laboratories said, DRILS Synergy is a forum to address the core opportunities and challenges in the industry. We strongly believe that collaboration between industry and academia will create a culture of innovation and great amount of research and productive work that can benefit the entire industry.

"DRILS has been doing a commendable job over the years and while we are proud to be associated with it"

*Refer synopsis overleaf

About Dr. Reddy's: Dr. Reddy's Laboratories Ltd. is an integrated pharmaceutical company, committed to accelerating access to affordable and innovative medicines, because it believes Good Health Can't Wait. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – the company offers a portfolio of products and services that include active pharmaceutical ingredients, (APIs), custom pharmaceutical services, generics, biosimilars and differentiated formulations. With operations in 26 countries across the globe, the major therapeutic areas of Dr. Reddy's are gastro-intestinal, cardiovascular, diabetology, oncology, pain management and anti-infectives. For more information, log on to: www.drreddys.com

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management's current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults, currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganisation, including related integration issues.

The company assumes no obligation to update any information contained herein.

Synopsis of Panel Discussions

Panel Discussion 1 - Synergistic Industry Academic Ecosystem: “Innovate in India

Panel Moderator: Prof. Goverdhan Mehta, National Research Professor, School of Chemistry, University of Hyderabad

Panel Members: Dr. K Nagrajan-Corp Advisor, Hikal Limited - Bengaluru
Dr. S Chandrasekhar - Director, IICT
Dr. Muthyala Ramaiah - Research Prof.- University of Minnesota ,Founder - Indian Organisation for Rare Diseases
Dr. Ashwin Nangia, Founder – Director, Crystalline Research Pvt Ltd., TBI Facility, University of Hyderabad
Dr. Amarnath Chaterjee – Scientific Manager- Biocon Ltd.

The conversation among the panel members revolved around addressing some of the key issues -

- Why innovation in India has not been at par with global peers?
- Despite having enormous talent in India, why the achievements in pharma innovation have not been commensurate?

The members were of the opinion that, academia can provide high quality and cost effective support to the industry players by working on specific requirements. A successful working model clubbed with a long term association of academics with pharma companies will lead to innovation and continuous value creation in the industry. The panel further outlined that, leveraging a mission like “Innovate in India” can accelerate the pace of research, innovation of new therapies, creation of new jobs and wealth for the industry.

Panel Discussion 2 – De-risking innovation and gearing up for the future: A perspective in the Life Sciences

Panel Moderator: Dr. D Balasubramanian, Director – LV Prasad Eye Institute

Panel Members: Prof. P. Reddanna , Dean , School of Life Sciences , UoH
Mr. Utkarsh Palnitkar, Partner & Head Advisory KPMG India
Dr. Uday Saxena , Co-founder Kareus Therapeutics SA
Ms. Deepanwita Chattopadhyay, Chairman & CEO-IKP Knowledge Park
Dr Radha Rangrajan, Founder- Director, Vitas Pharma, Technology Business Incubator, University of Hyderabad

The debate among the panel members was around –

- How can industries align their resources to access domain knowledge and high quality skill sets from academia?
- Role played by research institutes like DRILS in de-risking innovation for industry?

The members discussed about how the industry perceives investing in R&D as a risky element, considering the uncertainty of the outcome. Linking industry and academia, the conversations further lead to understanding research and innovation in life sciences in India, evaluating current perceptions and developing a risk-mitigation strategies.

About Dr. Reddy’s Institute of Life Sciences

Dr. Reddy’s Institute of Life Sciences is an autonomous body, originally incorporated in 2004 as Institute of Life Sciences (ILS). It is a not-for-profit organization set up under public-private partnership (PPP) model, between Govt. of Andhra Pradesh & University of Hyderabad as the Public partners and Dr. Reddy’s Laboratories Pvt Ltd as Private Pharma Industry. DRILS has an unique combination of scientific & R&D professionals from both industry and academia working in collaboration to meet specific research requirements of the industry.